1. Summary of 34 Key Studies over the Past Decade That Used Clinical Proteomics AD/ADRD with Demographic Information.
| clinical proteomics studies for AD/ADRD | clinical proteomics approach | key proteins identified | population demographics | type of tissues samples used | year published |
|---|---|---|---|---|---|
| Seifar et al. | MS | 9899 | 1385 , , | brain | 2024 |
| Nilsson et al. | MS and immunoprecipitation | SNAP-25, 14-3-3 zeta/delta, β-synuclein, and neurogranin | 958 participants from the Swedish BioFINDER-2 study, Skåne University Hospital, Lund, Sweden | CSF | 2024 |
| Haque et al. | MS | 48 | 706 individuals from ADNI | CSF | 2023 |
| Johnson et al. | MS | 33 | 475 samples from DIAN at Washington University | CSF | 2023 |
| Montoliu-Gaya et al. | IP/MS | p-tau181, p-tau199, p-tau202, p-tau205, p-tau217, p-tau231, tau195–205 and tau212–221 | 214 participants from the Paris Lariboisière and Translational Biomarkers of Aging & Dementia cohorts | plasma | 2023 |
| Modeste et al. | MS | 402 | 203 , | CSF | 2023 |
| Weiner et al. | MS and CLEIA | SCRN1 and tau | 244 patients from University of California San Diego Shiley–Marcos Alzheimer’s Disease Research Center | CSF | 2023 |
| Dammer et al. | MS, Olink, and SomaLogic SomaScan | >9500 | 154 samples from the Emory ADRC | brain, CSF, and plasma | 2022 |
| Gobom et al. | MS and Simoa | pT181, pS199, pS202, pT205, pT217, pT231, and pS396 | 38 samples from Sahlgrenska University Hospital, Mölndal, Sweden | CSF | 2022 |
| Johnson et al. | MS | 8600 | 516 from ROSMAP | brain | 2022 |
| Dey et al. | MS | >3000 | 16 samples from Banner Sun Health Research Institute | CSF | 2022 |
| Carlyle et al. | Olink | 414 | 54 subjects from Massachusetts ADRC cohort | plasma | 2022 |
| Kirmess et al. | MS | APOE2/2, APOE2/3, APOE2/4, APOE3/3, APOE3/4, APOE4/4, Aβ40 and Aβ42 | 5 pooled samples for C2N Diagnostics commercial PrecivityAD Test | plasma | 2021 |
| Bai et al. | Meta-analysis | 2698 | 7 deep data sets | brain, CSF, serum | 2021 |
| Khan et al. | MS | 25 | 113 , | plasma | 2021 |
| Florentinus-Mefailoski et al. | MS | 50 | 24 samples from Vrije Universiteit Amsterdam | plasma | 2021 |
| Tijms et al. | MS and ELISA | 705 | 552 participants from EMIF-AD MBD and the ADNI | CSF | 2020 |
| Bader et al. | MS | 867 | 197 from Sweden & Magdeburg/Kiel cohorts | CSF | 2020 |
| Higginbotham et al. | MS | 3691 | 40 samples from the Emory ADRC | CSF | 2020 |
| Ping et al. | MS | 8415 | 27 samples from Emory ADRC | brain | 2020 |
| Stepler et al. | MS | 568 | 55 , | brain | 2020 |
| Barthélemy et al. | MS and Immunoassay (pT181 and t-tau) | tau | 474 by the DIAN | CSF | 2020 |
| Zhou et al. | MS | SMOC1, YWHAZ, ALDOA and MAP1B | 88 from the Emory ADRC | CSF | 2020 |
| Shi et al. | SOMAscan | 44 | 881 from EMIF-AD MBD study | plasma | 2019 |
| Sathe et al. | MS | 139 | 10 samples from BIOCARD study | CSF | 2019 |
| Dey et al. | MS | 30 | 11 collected from Banner Sun Health Research Institute | serum | 2019 |
| Morris et al. | ELISA | Aβ42, p-tau181, t-tau | 1255 , | CSF | 2019 |
| Whelan et al. | Olink ProSeek immunoassay | 270 | 1022 samples from the Swedish BioFINDER study | CSF and plasma | 2019 |
| Ovod et al. | IP/MS | Aβ38, Aβ40, and Aβ42 | 41 participants from Washington University ADRC | plasma | 2018 |
| Johnson et al. | MS | 350 | 47 samples from Emory ADRC | brain | 2018 |
| Abreha et al. | MS | 1682 | 10 samples from the Emory ADRC | brain | 2018 |
| Hales et al. | MS | 2771 | 35 samples from the BLSA | brain | 2017 |
| Dammer et al. | MS | 142 | 16 samples from the Emory ADRC | brain | 2015 |
| Sattlecker et al. | SOMAscan | 13 | 691 samples from AddNeuroMed biomarker study | plasma | 2014 |
a
African Americans.
b
Hispanic/Latino Americans.
c
Non-Hispanic White.
d
Unknown population breakdown; ADNI - Alzheimer’s Disease Neuroimaging Initiative; ADRC - Alzheimer’s Disease Research Center; BIOCARD - Biomarkers for Older Controls at Risk for Dementia; BLSA - Baltimore Longitudinal Study of Aging; CLEIA - Chemiluminescent enzyme immunoassay; DIAN - Dominantly Inherited Alzheimer Network; ELISA -Enzyme-linked immunosorbent assay; EMIF-AD MBD - European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery; IP/MS - immunoprecipitation mass spectrometry; MS - Mass Spectrometry; ROSMAP - Religious Orders Study and Memory and Aging Project.